

**UNCLASSIFIED**

**Exhibit R-2, RDT&E Budget Item Justification:** PB 2012 Army **DATE:** February 2011

<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>				<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>							
<b>COST (\$ in Millions)</b>	<b>FY 2010</b>	<b>FY 2011</b>	<b>FY 2012 Base</b>	<b>FY 2012 OCO</b>	<b>FY 2012 Total</b>	<b>FY 2013</b>	<b>FY 2014</b>	<b>FY 2015</b>	<b>FY 2016</b>	<b>Cost To Complete</b>	<b>Total Cost</b>
Total Program Element	37.572	34.474	27.160	-	27.160	41.872	47.711	48.204	48.177	Continuing	Continuing
812: <i>MIL HIV VAC&amp;DRUG DEV</i>	4.296	4.456	3.866	-	3.866	2.949	4.329	4.490	4.486	Continuing	Continuing
832: <i>Field Medical Systems Engineering Development</i>	15.104	17.791	14.807	-	14.807	23.719	27.720	27.835	28.141	Continuing	Continuing
849: <i>INFEC DIS DRUG/VACC ED</i>	13.193	12.227	8.487	-	8.487	13.631	14.728	15.131	15.178	Continuing	Continuing
A11: <i>LSTAT MEDICAL TECHNOLOGY (CA)</i>	0.800	-	-	-	-	-	-	-	-	0.000	0.800
CS5: <i>MED MATERIEL/MED BIO DEFENSE INITIATIVES (CA)</i>	4.179	-	-	-	-	-	-	-	-	0.000	4.179
VS8: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - END DEV</i>	-	-	-	-	-	1.573	0.934	0.748	0.372	Continuing	Continuing

**Note**

FY12 funds realigned (\$2899) to higher priority requirements.

**A. Mission Description and Budget Item Justification**

This program element (PE) funds advanced development of medical materiel within the System Demonstration and Low Rate Initial Production portions of the acquisition life cycle using 6.5 funding. It supports products successfully developed in the Systems Integration portion of the Systems Development and Demonstration phases through completion of the Milestone C Decision Review. Commercially-off-the-shelf (COTS) medical products are also tested and evaluated for military use, when available. This PE primarily includes pivotal (conclusive) human clinical trials necessary for licensure by the Food and Drug Administration.

(PROJ 832) this project funds the engineering and manufacturing development of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. Mature commercial-off-the-shelf (COTS) medical products are also evaluated for military use. Consideration will also be given to reduce the medical sustainment footprint through smaller weight and cube volume, or equipment independence from supporting materiel. Products from this project will normally transition to OPA Funds.

(PROJ 812) project funds military relevant human immunodeficiency virus (HIV) medical countermeasures. These funds provide for engineering and manufacturing development of candidate vaccines and drugs to permit large-scale field testing. Development focused on military unique needs effecting manning, mobilization, and deployment. Products from this project will normally transition to DoD Health Programs or OPA Funds.

(PROJ 849) funds development of candidate medical countermeasures for military relevant infectious diseases. These products fall between four major areas: vaccines, drugs, diagnostic kits/devices, and insect control measures to limit exposure and disease transmission. FDA approval is a mandatory obligation for all military

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-2, RDT&amp;E Budget Item Justification:</b> PB 2012 Army	<b>DATE:</b> February 2011
---	----------------------------

<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>
---	---

products placed into the hands of medical providers or service members for human use. Products from this project will normally transition to DoD Health Programs or OPA funds.

This program is managed by U.S. Army Medical Materiel Development Activity (USAMMDA) and U.S. Army Medical Materiel Agency (USAMMA) of the US Army Medical Research and Materiel Command.

<b>B. Program Change Summary (\$ in Millions)</b>	<b><u>FY 2010</u></b>	<b><u>FY 2011</u></b>	<b><u>FY 2012 Base</u></b>	<b><u>FY 2012 OCO</u></b>	<b><u>FY 2012 Total</u></b>
Previous President's Budget	41.794	34.474	30.059	-	30.059
Current President's Budget	37.572	34.474	27.160	-	27.160
Total Adjustments	-4.222	-	-2.899	-	-2.899
• Congressional General Reductions		-			
• Congressional Directed Reductions		-			
• Congressional Rescissions	-	-			
• Congressional Adds		-			
• Congressional Directed Transfers		-			
• Reprogrammings	-3.099	-			
• SBIR/STTR Transfer	-1.123	-			
• Adjustments to Budget Years	-	-	-2.899	-	-2.899

**UNCLASSIFIED**

**UNCLASSIFIED**

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army								DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT 812: MIL HIV VAC&DRUG DEV			
COST (\$ in Millions)	FY 2010	FY 2011	FY 2012 Base	FY 2012 OCO	FY 2012 Total	FY 2013	FY 2014	FY 2015	FY 2016	Cost To Complete	Total Cost
812: MIL HIV VAC&DRUG DEV	4.296	4.456	3.866	-	3.866	2.949	4.329	4.490	4.486	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification											
This project funds militarily relevant human immunodeficiency virus (HIV) medical countermeasures. These funds provide for engineering and manufacturing development of candidate vaccines and drugs to permit large-scale field testing. Development is focused on militarily unique needs effecting manning, mobilization, and deployment.											
The major contractor is The Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD. Research efforts are coordinated with the National Institutes of Health.											
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)								FY 2010	FY 2011	FY 2012	
Title: Military HIV Vaccine and Drug Development  Articles:  Description: This project provides funds for engineering and manufacturing development of candidate vaccines and drugs to permit large-scale field testing of vaccines for medical countermeasures to HIV.  FY 2010 Accomplishments: prepared preliminary clinical study report on the completed expanded safety/efficacy trial in Thailand and conduct a critical design review (CDR) to determine future development of the prime-boost vaccine based on trial results. Follow up clinical trial for HIV positive for viral load in order to validate viral load as a surrogate endpoint for use in HIV vaccine studies.  FY 2011 Plans: Finalize and submit to the Food and Drug Administration (FDA) results from the expanded safety/efficacy trial in Thailand, update/revise the clinical development plan, and continue to follow up clinical trial for HIV positive for viral load.  FY 2012 Plans: Perform three inter-related studies to enhance our understanding of precisely how the vaccine strategy used in the safety/efficacy trial completed in 2009 caused vaccine recipients to be protected from infection, including intense laboratory studies using samples from the trial, and commencement of two small clinical vaccine trials to generate data and samples to hopefully define what vaccine responses to try to generate for next increment studies.								4.296	4.456	3.866	
								0	0		
Accomplishments/Planned Programs Subtotals								4.296	4.456	3.866	

**UNCLASSIFIED**

UNCLASSIFIED

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2012 Army		<b>DATE:</b> February 2011
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	<b>PROJECT</b> 812: <i>MIL HIV VAC&amp;DRUG DEV</i>
<b>C. Other Program Funding Summary (\$ in Millions)</b> N/A		
<b>D. Acquisition Strategy</b> Test and evaluate commercially developed vaccine candidates in government-managed trials.		
<b>E. Performance Metrics</b> Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.		

**UNCLASSIFIED**

Exhibit R-3, RDT&E Project Cost Analysis: PB 2012 Army										DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT 812: MIL HIV VAC&DRUG DEV					
Management Services (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	Various	Various:Various	0.672	0.091		0.215		-		0.215	Continuing	Continuing	0.000
Subtotal			0.672	0.091		0.215		-		0.215			0.000
Product Development (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Product Development	Various	Henry M. Jackson Foundation,:Various	21.570	3.231		2.655		-		2.655	Continuing	Continuing	Continuing
Subtotal			21.570	3.231		2.655		-		2.655			
Support (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	Various	Various:Various	0.487	0.046		0.046		-		0.046	Continuing	Continuing	0.000
Subtotal			0.487	0.046		0.046		-		0.046			0.000
Test and Evaluation (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Product Development	Various	Henry M. Jackson Foundation,:Various	21.570	1.088		0.950		-		0.950	Continuing	Continuing	Continuing
Subtotal			21.570	1.088		0.950		-		0.950			

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-3, RDT&amp;E Project Cost Analysis:</b> PB 2012 Army						<b>DATE:</b> February 2011			
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>			<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>			<b>PROJECT</b> 812: <i>MIL HIV VAC&amp;DRUG DEV</i>			
	<b>Total Prior Years Cost</b>	<b>FY 2011</b>	<b>FY 2012 Base</b>	<b>FY 2012 OCO</b>	<b>FY 2012 Total</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>	
<b>Project Cost Totals</b>	44.299	4.456	3.866	-	3.866				

**Remarks**

**UNCLASSIFIED**

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2012 Army																DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY								R-1 ITEM NOMENCLATURE								PROJECT			
2040: Research, Development, Test & Evaluation, Army								PE 0604807A: Medical Materiel/Medical								812: MIL HIV VAC&DRUG DEV			
BA 5: Development & Demonstration (SDD)								Biological Defense Equipment - Eng Dev											
</																			

**UNCLASSIFIED**

<b>Exhibit R-4A, RDT&amp;E Schedule Details:</b> PB 2012 Army			<b>DATE:</b> February 2011
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	<b>PROJECT</b> 812: <i>MIL HIV VAC&amp;DRUG DEV</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
HIV Vaccine Critical Design Review (CDR)	3	2010	3	2010

**UNCLASSIFIED**

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army									DATE: February 2011		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT 832: Field Medical Systems Engineering Development			
COST (\$ in Millions)	FY 2010	FY 2011	FY 2012 Base	FY 2012 OCO	FY 2012 Total	FY 2013	FY 2014	FY 2015	FY 2016	Cost To Complete	Total Cost
832: Field Medical Systems Engineering Development	15.104	17.791	14.807	-	14.807	23.719	27.720	27.835	28.141	Continuing	Continuing
Quantity of RDT&E Articles											

**A. Mission Description and Budget Item Justification**

This project funds the engineering and manufacturing development of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. This project funds pivotal (conclusive) human clinical trials or mechanical engineering evaluations for efficacy of devices or biologics (products derived from living organisms) to fulfill unique military requirements. Mature commercial-off-the-shelf (COTS) medical products are also evaluated for military use. Consideration will also be given to reducing the medical sustainment footprint through smaller weight and cube volume, or equipment independence from supporting materiel. This work is frequently completed through a laboratory/contractor team with the contractor obtaining the U.S. Food and Drug Administration (FDA) licensure for sale of the product.

In FY10, Project 834 Soldier Sys Prot-ED was consolidated into Project 832.

Major contractors/intra-governmental agencies include: IGR Enterprises, Inc.; Army Medical Department Board Test Center; SeQual Technologies, Inc.; Enginivity, Inc.; Ultrasound Diagnostics, Inc.; HemCon Medical Technologies, Inc.; Cerdak Ltd; Hemerus Medical, LLC; Fast Track Drugs & Biologics, LLC; Integrated Medical Systems, Inc; the National Institutes of Health National Heart, Lung and Blood Institute (NHLBI), and the U.S. Army Aeromedical Research Laboratory Walter Reed Army Institute of Research (WRAIR) and Institute of Surgical Research (ISR) for user evaluation. Other military agencies include Program Executive Office (PEO) Soldier, PEO Combat Service Support (CSS), and Naval Undersea Warfare Center.

**B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)**

	<b>FY 2010</b>	<b>FY 2011</b>	<b>FY 2012</b>
<b>Title:</b> Medical Materiel/Medical Biological Defense Equipment- Engineering Development FY 10 and 11	15.104	17.791	-
<b>Articles:</b>	0	0	
<b>Description:</b> This project funds in FY 10 and 11 the engineering and manufacturing development of medical products for enhanced combat casualty care and follow-on care, including rehabilitation.			
<b>FY 2010 Accomplishments:</b> Ceramic Oxygen Generator: conducted developmental and operational testing to obtain Milestone C. Follow on testing and report analysis was performed to facilitate FDA and UL approval and ascertain that production capabilities adhere to good manufacturing practices. Further analyses were performed to facilitate FDA and UL approval and ascertain that production capabilities adhere to good manufacturing processes. In 2Q FY10 for the RVPSAOG submitted final reports for FDA clearance. Field Sterilizer: completed analysis and validation report of down selected products in OT&E trials for final selection and movement to production and deployment. Ultrasonic Brain Imager (UBI): transitioned from project 836, began safety and effectiveness human clinical trial,			

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2012 Army			<b>DATE:</b> February 2011		
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>		<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>		<b>PROJECT</b> 832: <i>Field Medical Systems Engineering Development</i>	
<b>B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)</b>			<b>FY 2010</b>	<b>FY 2011</b>	<b>FY 2012</b>
<p>conducted a human factor evaluation of the prototype, and conducted a Milestone C for transition to Production and Deployment. Freeze Dried Plasma Program: initiated a multi-center safety/efficacy human clinical trial, and performed stability studies on product. Red blood cell extended life program: prepared and completed enrollment in human safety/efficacy study. Woundstat Safety Study: completed the study. Continued testing of commercial lab equipment: expanded study to include Hematology Analyzers continued testing and evaluation for final report in 3Q FY10. Noise immune stethoscope: conducted environmental/ transportation testing. Verified stethoscope will be able to stand up to the military environment. Conducted storage and operational temperature, drop and vibration, as well as air-worthiness testing. Life Support for Trauma and Transport (LSTAT): transitioned from project 834.</p> <p><b>FY 2011 Plans:</b></p> <p>In FY11, Freeze-dried Plasma: start enrollment in the multi-center limited human safety/efficacy clinical trial and evaluate stability profile of the product. Red Blood Cell Extended Life Program: complete the human safety/efficacy study, conduct data analysis, and prepare and submit report to the FDA. Platelet Derived Hemostatic Agent (PDHA): transition from project 836 to begin enrollment/follow-up in the human safety/efficacy trial. Intranasal Ketamine (low dose pain management via nasal spray): transition from project 836 and conduct pre-clinical trial activities for human drug use in aeromedical evacuation and burn patients. Hypertonic Saline Dextran (treatment of shock due to blood loss): support human expanded safety/efficacy trial for treatment of shock. Continue market analysis and surveys for candidate resuscitative fluids for treatment of shock. Enhanced SAVe: Conduct clinical user evaluation and operational testing. Remote Diagnostic Access: Conduct Prototype field testing and refinement for MOC Sensor Modul Development phase of this device. Treatment Table for PM, HBCT Medical Mission Package for Treatment Variants: Transition from Project 836. Transition to production for use on PM, HBCT Treatment Variant. Refrigerator for PM, HBCT for Medical Mission Package for Treatment Variant: Transition from Project 836. Conduct environmental and operational testing. Shelter for PM, HBCT Treatment Variant: Transition from Project 836. Evaluate alternatives in operational setting. Shock and Vibration Isolation System for Patient Litters in Ground and Air Medical Evacuation Vehicles: Transition from Project 836. Conduct Shock and Vibration Isolation System for patient litters - air worthiness and ground vehicle testing. One-handed tourniquet update: Conduct study to update medical set and down select product. Passive Cold Chain Capability for Temperature Sensitive Medical Materiel: Transition from Project 836. Conduct environmental testing and user testing.</p>					
<p><b>Title:</b> Field Medical Systems Engineering Development FY 12 PM Medical Devices</p> <p><b>Description:</b> This project funds in FY 12 the engineering and manufacturing development of medical products for enhanced combat casualty care managed by PM Medical Devices.</p> <p><b>FY 2012 Plans:</b></p> <p>: The Burn Resuscitation Decision Device: Will conduct final environmental, operational and clinical testing on device for MS C submission. Wireless Medical Monitoring will transition from Congressional Special Interest (CSI) project to an Army Core funded</p>			-	-	6.033

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2012 Army			<b>DATE:</b> February 2011		
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>		<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>		<b>PROJECT</b> 832: <i>Field Medical Systems Engineering Development</i>	
<b>B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)</b>			<b>FY 2010</b>	<b>FY 2011</b>	<b>FY 2012</b>
project and will undergo a Milestone C review as well as prototype field testing. Plasma Knife: Will transition from 836 6.4 funding line into 832 6.5 funding line. Will finalize results of clinical and operational testing. Will also identify and address all refinements and undergo Milestone C review in 4Q.					
<b>Title:</b> Field Medical Systems Engineering Development FY 12 PM Pharmaceuticals <b>Description:</b> This project funds in FY 12 the engineering and manufacturing development of medical products managed by PM Pharmaceuticals for enhanced combat casualty care and follow-on care, including rehabilitation. <b>FY 2012 Plans:</b> Freeze-dried Plasma: Will begin enrollment in a multi-center limited human safety/efficacy clinical trial; will improve manufacturing & laboratory capabilities to meet Food and Drug Administration requirements; and will evaluate stability profile of the product. Cryopreserved Platelets (CPP) (formerly Platelet Derived Hemostatic Agent (PDHA)): Will continue enrollment/follow-up in a human safety/efficacy trial.			-	-	5.034
<b>Title:</b> Field Medical Systems Engineering Development FY 12 PM Integrated Clinical Systems (ICS) <b>Description:</b> This project funds in FY 12 the engineering and manufacturing development of medical products managed by PM ICS for enhanced combat casualty care and follow-on care, including rehabilitation. <b>FY 2012 Plans:</b> Will conduct final testing of Phase IV of Remote Access Device (RDA). Will Develop a universal security compliant access portal to serve as a standardized compliance wrapper for all vendors, medical technology, and even IT management products that may traverse between the .com and .mil networks. The Milestone Decision Authority (MDA) has scheduled an in process review for the RDA project in March 2011 .			-	-	0.737
<b>Title:</b> Field Medical Systems Engineering Development FY 12 PM Medical Support Systems <b>Description:</b> This project funds in FY 12 the engineering and manufacturing development of medical products managed by PM Medical Support Systems for enhanced combat casualty care and follow-on care, including rehabilitation. <b>FY 2012 Plans:</b> PM will collaborate with PM HBCT on medical equipment for the future treatment vehicle variant. PM will test and evaluate the shock and litter isolation system for potential addition to Ground Ambulance and Air Ambulance Medical Equipment Sets (MES). Continue to transition to Force Provider by fielding a Force Provider CSH. PM will fully test the new 2-sided ISO shelter under the Joint shelter Program and finalize acquisition strategy in coordination with Program Manager's Force Provider program. PM will			-	-	3.003

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2012 Army		<b>DATE:</b> February 2011	
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	<b>PROJECT</b> 832: <i>Field Medical Systems Engineering Development</i>	
<b>B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)</b>		<b>FY 2010</b>	<b>FY 2011</b>
continue to develop Medical Evacuation Vehicles in coordination with Program Executive Office Combat Service Support vehicle developers.			
<b>Accomplishments/Planned Programs Subtotals</b>		15.104	14.807
<b>C. Other Program Funding Summary (\$ in Millions)</b> N/A			
<b>D. Acquisition Strategy</b> Develop in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding.			
<b>E. Performance Metrics</b> Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.			

**UNCLASSIFIED**

Exhibit R-3, RDT&E Project Cost Analysis: PB 2012 Army										DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY				R-1 ITEM NOMENCLATURE				PROJECT					
2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				832: Field Medical Systems Engineering Development					
Management Services (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1Million individually	Various	Various:Various	20.127	1.429		0.418		-		0.418	Continuing	Continuing	Continuing
Subtotal			20.127	1.429		0.418		-		0.418			
Product Development (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Rotary Valve Pressure Swing Adsorption oxygen Generator	Various	Sequal Technologies,Inc.:;Various	3.497	-		-		-		-	Continuing	Continuing	Continuing
Hypertonic Saline Dextran	Various	National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI):;Various	4.800	5.500		-		-		-	Continuing	Continuing	Continuing
Freeze-dried Human Plasma	Various	HemCon Medical Technologies, Inc.;Tigard OR	10.405	0.500		5.796		-		5.796	Continuing	Continuing	Continuing
Extended Life Red Blood Cell Product	Various	Hemerus Medical, LLC.;Various	1.895	0.500		-		-		-	Continuing	Continuing	Continuing
Virtual Imaging	Various	Virtual Imaging:various	1.450	-		-		-		-	Continuing	Continuing	Continuing
No product/contract costs greater than \$1M individually	Various	Various:various	1.260	2.000		-		-		-	Continuing	Continuing	Continuing
Cryopreserved Platelets	Various	Multiple DoD activities and Dartmouth Hitchcock Med Ctr:North Potomac, MD	-	-		7.757		-		7.757	Continuing	Continuing	Continuing
Subtotal			23.307	8.500		13.553		-		13.553			

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-3, RDT&amp;E Project Cost Analysis:</b> PB 2012 Army											<b>DATE:</b> February 2011		
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>				<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>				<b>PROJECT</b> 832: <i>Field Medical Systems Engineering Development</i>					
<b>Support (\$ in Millions)</b>				<b>FY 2011</b>		<b>FY 2012 Base</b>		<b>FY 2012 OCO</b>		<b>FY 2012 Total</b>			
<b>Cost Category Item</b>	<b>Contract Method &amp; Type</b>	<b>Performing Activity &amp; Location</b>	<b>Total Prior Years Cost</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
Regulatory Support	Various	Clinical Research Management, Inc.,: Various	2.757	1.400		-		-		-	Continuing	Continuing	Continuing
No product/contract costs greater than \$1 Million individually	Various	Various: Various	1.788	2.354		0.418		-		0.418	Continuing	Continuing	Continuing
<b>Subtotal</b>			4.545	3.754		0.418		-		0.418			
<b>Test and Evaluation (\$ in Millions)</b>				<b>FY 2011</b>		<b>FY 2012 Base</b>		<b>FY 2012 OCO</b>		<b>FY 2012 Total</b>			
<b>Cost Category Item</b>	<b>Contract Method &amp; Type</b>	<b>Performing Activity &amp; Location</b>	<b>Total Prior Years Cost</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
No product/contract costs greater than \$1 Million individually	Various	Various: Various	3.417	4.108		0.418		-		0.418	Continuing	Continuing	Continuing
<b>Subtotal</b>			3.417	4.108		0.418		-		0.418			
<b>Project Cost Totals</b>			<b>Total Prior Years Cost</b> 51.396	<b>FY 2011</b> 17.791		<b>FY 2012 Base</b> 14.807		<b>FY 2012 OCO</b> -		<b>FY 2012 Total</b> 14.807	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
<b>Remarks</b>													

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-4, RDT&amp;E Schedule Profile:</b> PB 2012 Army			<b>DATE:</b> February 2011		
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>		<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>		<b>PROJECT</b> 832: <i>Field Medical Systems Engineering Development</i>	

	FY 2010				FY 2011				FY 2012				FY 2013				FY 2014				FY 2015				FY 2016			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
(1) Ceramic Oxygen Gen Sys (MS-C)																												
(6) Ultrasonic Brain Imager (MS-C)																												
Total Intravenous Anesthesia (TIVA) (MS-C)																												
Burn Resuscitation Decision Device (MS-C)																												
Wireless Medical Monitoring (MS-C)																												
Plasma Knife (MS-C)																												

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-4A, RDT&amp;E Schedule Details:</b> PB 2012 Army			<b>DATE:</b> February 2011
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	<b>PROJECT</b> 832: <i>Field Medical Systems Engineering Development</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
(1) Ceramic Oxygen Gen Sys (MS-C)	3	2010	3	2010
(6) Ultrasonic Brain Imager (MS-C)	1	2010	1	2010
Total Intravenous Anesthesia (TIVA) (MS-C)	4	2012	4	2012
Burn Resuscitation Decision Device (MS-C)	1	2012	1	2012
Wireless Medical Monitoring (MS-C)	3	2012	3	2012
Plasma Knife (MS-C)	1	2012	1	2012

**UNCLASSIFIED**

Exhibit R-2A, RDT&E Project Justification: PB 2012 Army								DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT 849: INFEC DIS DRUG/VACC ED			
COST (\$ in Millions)	FY 2010	FY 2011	FY 2012 Base	FY 2012 OCO	FY 2012 Total	FY 2013	FY 2014	FY 2015	FY 2016	Cost To Complete	Total Cost
849: INFEC DIS DRUG/VACC ED	13.193	12.227	8.487	-	8.487	13.631	14.728	15.131	15.178	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification											
This project funds development of candidate medical countermeasures for militarily relevant infectious diseases. These products fall within four major areas: vaccines, drugs, diagnostic kits/devices, and insect control measures to limit exposure and disease transmission. It funds research that supports conclusive human clinical trials for large-scale human efficacy testing, expanded human safety clinical trials, long-term animal studies, and related manufacturing tests. This work, which is jointly performed by military laboratories, civilian contracted pharmaceutical firms and foreign research partners, is directed toward the prevention of disease, early diagnosis, and speeding recovery once diagnosed. Medical products approved for human use must successfully complete a series of clinical trials that are required and regulated by the U.S. Food and Drug Administration (FDA). FDA approval is a mandatory obligation for all military products placed into the hands of medical providers or service members for human use. Development priority is based upon four major factors: (1) the extent of the disease within the Combatant Commands' theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development, production, and sustainment). Malaria, dysentery, hepatitis, and dengue diseases (a severe debilitating disease transmitted by mosquitoes), which are found in Africa Command, Central Command, European Command, Southern Command, and Pacific Command areas are at the top of the infectious diseases requirements list.											
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)								FY 2010	FY 2011	FY 2012	
Title: FY 10 Malaria Drug/ Vaccine Engineering Development  Articles:  Description: This project funds in FY 10 development of candidate medical countermeasures for militarily relevant infectious diseases.  FY 2010 Accomplishments: Conducted clinical trials, developmental testing, and reviews of malarial/antimalarial vaccines, drugs, diagnostics and insect repellents. For Tafenoquine, conducted data analysis and prepared a final report on the small human challenge clinical trial, and began pre-trial activities for a large-scale safety/efficacy human clinical trial (treatment indication) in a malaria endemic country.  FY 2011 Plans: Will conduct clinical trials, developmental testing, and reviews of malarial/antimalarial vaccines, drugs, diagnostics and insect repellents. For Tafenoquine, will complete pre-trial activities for a large-scale safety/efficacy human clinical trial (treatment indication) in a malaria endemic country.								6.018	4.568	-	
								0	0		
Title: FY 10 Infectious Disease Drug and Vaccine Engineering Development  Articles:								7.175	7.659	8.487	
								0	0		

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2012 Army		<b>DATE:</b> February 2011	
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	<b>PROJECT</b> 849: <i>INFEC DIS DRUG/VACC ED</i>	
<b>B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)</b>		<b>FY 2010</b>	<b>FY 2011</b>
<p><b>Description:</b> FY 10 funding for research and development efforts described below.</p> <p><b>FY 2010 Accomplishments:</b> Topical Antileishmanial Cream [Leishmaniasis is a skin-based disease caused by a parasite and transmitted by sand flies], continued subject enrollment/follow-up in the Tunisia large scale (&gt; 300 subjects) human safety/efficacy trial and began pretrial activities of the second large scale human safety/efficacy trial in Central/South America, and completed study start of three small scale (&lt;35 subjects) pharmacokinetic (drug metabolism) human trials in France, Peru and Panama. For Pentostam (intravenous drug treatment of skin lesions caused by the Leishmania parasite), monitored progress of industry partner's FDA licensure submission efforts. Since industry partner has chosen not to submit for FDA Licensure, continued a human treatment protocol in the U.S. For Dengue Tetravalent Vaccine [Dengue is a severe debilitating disease caused by a virus and transmitted by a mosquito], completed subject follow-up and began data analysis on the expanded human safety and immunity trial in Puerto Rico, prepared the study report on the human safety and immune response trial (adults) in the U.S., prepared the study reports (infant, children and adult) on the expanded human safety and immune response trial in Thailand, and completed pre-trial activities for the expanded safety and efficacy trial in children in Thailand. For Hepatitis E vaccine, continued maintenance of study blood specimens kept under cold storage and monitoring of industry partner's Hepatitis E vaccine development effort.</p> <p><b>FY 2011 Plans:</b> In FY11, for Topical Antileishmanial Cream, analyze the data and prepare the final report on the Tunisia large scale human safety/efficacy trial, continued pretrial activities for enrollment in the second large scale (&gt; 300 subjects) human safety/efficacy trial in Central/South America, and will analyze the data and prepare the final report for the three small scale (&lt;35 subjects) pharmacokinetic (drug metabolism) human trials in France, Peru and Panama. For Pentostam, will continue a human treatment protocol in the U.S. For DTV vaccine, will complete the study report on the expanded human safety and immunity trial in Puerto Rico and begin the expanded safety and efficacy trial in children in Thailand. For Hepatitis E vaccine will continue maintenance of study blood specimens kept under cold storage and monitoring of industry partner's Hepatitis E vaccine development effort.</p> <p><b>FY 2012 Plans:</b> Will conduct Clinical trials, developmental testing, and reviews of malarial/antimalarial vaccines, drugs, diagnostics and insect repellents. Will down-select from candidate anti-malaria drugs (e.g. Tafenoquine and other drugs) to prepare for clinical trial activities for a safety/efficacy human clinical trial (treatment indication) in a malaria endemic country. Will conduct clinical trials, developmental testing, and appropriate reviews of grouped vaccines, drugs, and diagnostics (Leishmaniasis (a skin-based disease caused by a parasite and transmitted by sand flies), Dengue (a severe debilitating disease caused by a virus and transmitted by a mosquito), and other viral diseases: For Topical Antileishmanial Cream, begin the clinical study report on the Tunisia large scale human safety/efficacy trial, begin enrollment efforts in the second large scale (&gt; 300 subjects) human safety/efficacy trial in Central/South America. For Dengue Tetravalent Vaccine (DTV) begin study close out activities for expanded</p>			

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2012 Army		<b>DATE:</b> February 2011	
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	<b>PROJECT</b> 849: <i>INFEC DIS DRUG/VACC ED</i>	
<b>B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)</b>		<b>FY 2010</b>	<b>FY 2011</b>
safety and efficacy trial in children in Thailand; begin a new DTV large scale (> 300 subjects) human trial in Thailand and Philippines to expand safety data and demonstrate efficacy in children/adults.			
<b>Accomplishments/Planned Programs Subtotals</b>		13.193	12.227
<b>C. Other Program Funding Summary (\$ in Millions)</b> N/A			
<b>D. Acquisition Strategy</b> Test and evaluate in-house and commercially developed products in government-managed trials to meet FDA requirements and Environmental Protection Agency registration.			
<b>E. Performance Metrics</b> Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.			

**UNCLASSIFIED**

Exhibit R-3, RDT&E Project Cost Analysis: PB 2012 Army											DATE: February 2011			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT 849: INFEC DIS DRUG/VACC ED						
Management Services (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
No product/contract costs greater than \$1M individually	Various	Various:Various	8.115	2.008		1.931		-		1.931	Continuing	Continuing	Continuing	
Subtotal			8.115	2.008		1.931		-		1.931				
Product Development (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
No product/contract costs greater than \$1M individually	Various	Various:Various	15.268	3.116		3.171		-		3.171	Continuing	Continuing	Continuing	
Subtotal			15.268	3.116		3.171		-		3.171				
Support (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
No product/contract costs greater than \$1M individually	Various	Various:Various	6.097	2.492		1.000		-		1.000	Continuing	Continuing	Continuing	
Subtotal			6.097	2.492		1.000		-		1.000				
Test and Evaluation (\$ in Millions)				FY 2011		FY 2012 Base		FY 2012 OCO		FY 2012 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
No product/contract costs greater than \$1M individually	Various	Various:Various	22.231	4.611		2.385		-		2.385	Continuing	Continuing	Continuing	
Subtotal			22.231	4.611		2.385		-		2.385				

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-3, RDT&amp;E Project Cost Analysis:</b> PB 2012 Army							<b>DATE:</b> February 2011		
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>			<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>			<b>PROJECT</b> 849: <i>INFEC DIS DRUG/VACC ED</i>			
	<b>Total Prior Years Cost</b>	<b>FY 2011</b>	<b>FY 2012 Base</b>	<b>FY 2012 OCO</b>	<b>FY 2012 Total</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>	
<b>Project Cost Totals</b>	51.711	12.227	8.487	-	8.487				
<b>Remarks</b>									

**UNCLASSIFIED**

<b>Exhibit R-4, RDT&amp;E Schedule Profile:</b> PB 2012 Army			<b>DATE:</b> February 2011		
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>		<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>		<b>PROJECT</b> 849: <i>INFEC DIS DRUG/VACC ED</i>	

	FY 2010				FY 2011				FY 2012				FY 2013				FY 2014				FY 2015				FY 2016			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Dengue Tetravalent Vaccine (CDR)																												
Dengue Tetravalent Vaccine Phase 3 Expanded Safety Study																												
Dengue Tetravalent Vaccine (MS-C)																												
Malaria Prophylaxis (MS-C)																												
Paromomycin/Gentamicin Topical Antileishmanial Cream (CDR)																												
Paromomycin/Gentamicin Topical Antileishmanial Cream Phase 3 Expa																												
Paromomycin/Gentamicin Topical Antileishmanial Cream MS-C																												
Paromomycin/Gentamicin Topical Antileishmanial Cream NDA																												
Paromomycin/Gentamicin Topical Antileishmanial Cream LRIP																												
Paromomycin/Gentamicin Topical Antileishmanial Cream F/D																												
Leishmania Rapid Diagnostic Device MS-C																												
Leishmania Rapid Diagnostic Device FDA Approval																												
Leishmania Rapid Diagnostic Device Fielding/Delivery																												

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-4A, RDT&amp;E Schedule Details:</b> PB 2012 Army			<b>DATE:</b> February 2011
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	<b>PROJECT</b> 849: <i>INFEC DIS DRUG/VACC ED</i>	

**Schedule Details**

<b>Events</b>	<b>Start</b>		<b>End</b>	
	<b>Quarter</b>	<b>Year</b>	<b>Quarter</b>	<b>Year</b>
Dengue Tetravalent Vaccine (CDR)	3	2011	4	2015
Dengue Tetravalent Vaccine Phase 3 Expanded Safety Study	3	2011	4	2016
Dengue Tetravalent Vaccine (MS-C)	3	2016	3	2016
Malaria Prophylaxis (MS-C)	4	2016	4	2016
Paromomycin/Gentamicin Topical Antileishmanial Cream (CDR)	4	2011	4	2013
Paromomycin/Gentamicin Topical Antileishmanial Cream Phase 3 Expa	2	2011	1	2013
Paromomycin/Gentamicin Topical Antileishmanial Cream MS-C	2	2014	2	2014
Paromomycin/Gentamicin Topical Antileishmanial Cream NDA	3	2014	3	2014
Paromomycin/Gentamicin Topical Antileishmanial Cream LRIP	4	2014	3	2015
Paromomycin/Gentamicin Topical Antileishmanial Cream F/D	4	2014	4	2014
Leishmania Rapid Diagnostic Device MS-C	4	2012	4	2012
Leishmania Rapid Diagnostic Device FDA Approval	1	2013	1	2013
Leishmania Rapid Diagnostic Device Fielding/Delivery	2	2013	4	2016

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2012 Army									<b>DATE:</b> February 2011		
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>				<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>				<b>PROJECT</b> A11: <i>LSTAT MEDICAL TECHNOLOGY (CA)</i>			
<b>COST (\$ in Millions)</b>	<b>FY 2010</b>	<b>FY 2011</b>	<b>FY 2012 Base</b>	<b>FY 2012 OCO</b>	<b>FY 2012 Total</b>	<b>FY 2013</b>	<b>FY 2014</b>	<b>FY 2015</b>	<b>FY 2016</b>	<b>Cost To Complete</b>	<b>Total Cost</b>
A11: <i>LSTAT MEDICAL TECHNOLOGY (CA)</i>	0.800	-	-	-	-	-	-	-	-	0.000	0.800
Quantity of RDT&E Articles											

**A. Mission Description and Budget Item Justification**  
The LSTAT is a life support piece of combat medical equipment. It is a litter with imbedded life support equipment, which is capable of sustaining an injured soldier for an extended period of time. This equipment will allow a soldier to be transported while maintaining all medical surveillance and diagnostics continually intact.

<b>B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)</b>	<b>FY 2010</b>	<b>FY 2011</b>	<b>FY 2012</b>
<b>Title:</b> LSTAT Medical Technology  <div style="text-align: right;"><b>Articles:</b></div> <b>Description:</b> This is a Congressional Interest Item.  <b>FY 2010 Accomplishments:</b> Advanced Product development research was conducted on the LSTAT.	0.800 0	-	-
<b>Accomplishments/Planned Programs Subtotals</b>	0.800	-	-

**C. Other Program Funding Summary (\$ in Millions)**  
N/A

**D. Acquisition Strategy**  
N/A

**E. Performance Metrics**  
Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.

**UNCLASSIFIED**

<b>Exhibit R-3, RDT&amp;E Project Cost Analysis:</b> PB 2012 Army											<b>DATE:</b> February 2011		
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>				<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>				<b>PROJECT</b> A11: <i>LSTAT MEDICAL TECHNOLOGY (CA)</i>					

  

<b>Product Development (\$ in Millions)</b>				<b>FY 2011</b>		<b>FY 2012 Base</b>		<b>FY 2012 OCO</b>		<b>FY 2012 Total</b>			
<b>Cost Category Item</b>	<b>Contract Method &amp; Type</b>	<b>Performing Activity &amp; Location</b>	<b>Total Prior Years Cost</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
No product/contract cost greater than \$1M individually	SS/LH	IMS Systems:Signal Hill, CA	4.471	-		-		-		-	Continuing	Continuing	Continuing
<b>Subtotal</b>			4.471	-		-		-		-			

  

	<b>Total Prior Years Cost</b>	<b>FY 2011</b>		<b>FY 2012 Base</b>		<b>FY 2012 OCO</b>		<b>FY 2012 Total</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
<b>Project Cost Totals</b>	4.471	-		-		-		-			

  

**Remarks**

**UNCLASSIFIED**

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2012 Army								<b>DATE:</b> February 2011			
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>				<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>				<b>PROJECT</b> CS5: <i>MED MATERIEL/MED BIO DEFENSE INITIATIVES (CA)</i>			
<b>COST (\$ in Millions)</b>	<b>FY 2010</b>	<b>FY 2011</b>	<b>FY 2012 Base</b>	<b>FY 2012 OCO</b>	<b>FY 2012 Total</b>	<b>FY 2013</b>	<b>FY 2014</b>	<b>FY 2015</b>	<b>FY 2016</b>	<b>Cost To Complete</b>	<b>Total Cost</b>
CS5: <i>MED MATERIEL/MED BIO DEFENSE INITIATIVES (CA)</i>	4.179	-	-	-	-	-	-	-	-	0.000	4.179
Quantity of RDT&E Articles											

**A. Mission Description and Budget Item Justification**  
Congressional Special Interest funding for medical materiel/medical biological defense initiatives - Engineering Development.

<b>B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)</b>	<b>FY 2010</b>	<b>FY 2011</b>	<b>FY 2012</b>
<b>Title:</b> Army Portable Oxygen Concentration System  <b>Articles:</b>  <b>Description:</b> This is a Congressional Interest Item.  <b>FY 2010 Accomplishments:</b> Conducted advanced development research in Army Portable Oxygen Concentration System	1.190 0	-	-
<b>Title:</b> Military applications for Medical Grade Chitosan  <b>Articles:</b>  <b>Description:</b> Congressional Interest Item.  <b>FY 2010 Accomplishments:</b> Conducted advanced development research project to conduct military applications for Medical Grade Chitosan	2.989 0	-	-
<b>Accomplishments/Planned Programs Subtotals</b>	4.179	-	-

**C. Other Program Funding Summary (\$ in Millions)**  
N/A

**D. Acquisition Strategy**  
N/A

**E. Performance Metrics**  
Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.

**UNCLASSIFIED**

**UNCLASSIFIED**

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2012 Army									<b>DATE:</b> February 2011		
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 5: <i>Development &amp; Demonstration (SDD)</i>				<b>R-1 ITEM NOMENCLATURE</b> PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>				<b>PROJECT</b> VS8: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - END DEV</i>			
<b>COST (\$ in Millions)</b>	<b>FY 2010</b>	<b>FY 2011</b>	<b>FY 2012 Base</b>	<b>FY 2012 OCO</b>	<b>FY 2012 Total</b>	<b>FY 2013</b>	<b>FY 2014</b>	<b>FY 2015</b>	<b>FY 2016</b>	<b>Cost To Complete</b>	<b>Total Cost</b>
VS8: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - END DEV</i>	-	-	-	-	-	1.573	0.934	0.748	0.372	Continuing	Continuing
Quantity of RDT&E Articles											
<p><b>A. Mission Description and Budget Item Justification</b> No FY12 Funding for this project</p> <p><b>B. Accomplishments/Planned Programs (\$ in Millions)</b> N/A</p> <p><b>C. Other Program Funding Summary (\$ in Millions)</b> N/A</p> <p><b>D. Acquisition Strategy</b> N/A</p> <p><b>E. Performance Metrics</b> Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.</p>											

**UNCLASSIFIED**